Polyaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 677-682

  Quesada, A R ^a   Garcia Gravalos M D ^b   Fernandez Puentes J L ^b  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b PHARMAMAR S A   (Spain)

Author keywords

Lamellarin; MDR1; Multidrug resistance; Resistance modifier; Verapamil

Indexed keywords

ALKALOID; DAUNORUBICIN; GLYCOPROTEIN P; POLYCYCLIC AROMATIC HYDROCARBON; RHODAMINE 123; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EFFUSION; INVERTEBRATE; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SEA POLLUTION; TUMOR CELL LINE;

EID: 0029761248     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.421     Document Type: Article

References (39)

1. ANDERSEN RJ, FAULKNER DJ, CUN-HENG H, VAN DUYNE GD AND CLARDY J. (1985). Metabolites of the marine prosobranch mollusc Lamellaria sp. J. Am. Chem. Soc., 107, 5492-5495.
2. ARCECI RJ. (1993). Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81, 2215-2222.
3. BECK WT AND QIAN XD. (1992). Photoaffinity substrates for P-glycoprotein. Biochem. Pharmacol., 43, 89-93.
4. BENCHIMOL S AND LING V. (1994). P-glycoprotein and tumor progression. J. Natl Cancer Inst., 86, 814-815.
5. BIEDLER JL. (1994). Drug resistance: genotype versus phenotype. Thirty-second G.H.A. Clowes Memorial Award Lecture. Cancer Res., 54, 666 678.
6. CARROLL AC, BOWDHN BF AND COLL JC. (1993). Studies of Australian ascidians, Didemnum sp. Aust. J. Chem., 46, 489 501.
7. CONFORTI G, CODEGONI AM, SCANZIANI K, DOLFINI E, DASDIA T, CALZA M, CANIATTI M AND BROGGINI M. (1995). Different vimentin expression in two clones derived from a human colocarcinoma cell line (Lo Vo) showing different sensitivity to doxorubicin. Br. J. Cancer, 71, 505 511.
8. GANAPATHI R AND GRABOWSKI D. (1983). Enhancement of sensitivity to doxorubicin in resistant P388 leukemia cells by the calmodulin inhibitor trifluoperazine. Cancer Res., 43, 3696 3699.
9. GOTTESMAN MM AND PASTAN I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385 427.
10. GRANDI M, GERONI C AND GIULIANI FC. (1986). Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br. J. Cancer, 54, 515 518.
11. GRANDI M, YOUNG C, BELLINI O, GERI O, MUINDI J AND GIULIANI F. (1987). Pleiotropic multidrug resistant Lo Vo, P388 and 1-407 cell lines have an increased tubulovesicular compartment. Proc. Am. Assoc. Cancer Res., 28, 279.
12. JACHEZ B, BOESCH D, GRASSBERGER MA AND LOOR F. (1993a). Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives. Anti-Cancer Drugs, 4, 223 229.
13. JACHEZ B, NORDMANN R AND LOOR F. (1993b). Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280 446. J. Natl Cancer Inst., 85, 478 483.
14. KARTNER N, EVERNDEN-PORELLE D, BRADLEY G AND LING V. (1985). Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature, 316, 820 823.
15. KELLER RP, ALTERMATT HJ, NOOTER K, POSCHMANN G, LAISSUE JA, BOLKINGER P AND HIESTAND PC. (1992). SDZ PSC 833, A non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50, 593 597.
16. LINDQUIST N, FENICAL W, VAN DUYNK G AND CLARDY J. (1988). New alkaloids of the lamellarin class from the marine ascidians Didemnum chartaceum (Sluiter, 1909). J. Org. Chem., 53, 4570 4574.
17. LING V. (1982). Genetic basis of drug resistance in mammalian cells. In Drug and Hormone Resistance in Neoplasia, Bruchovski N and Goldie JM (eds), Vol. 1 pp. 1 19, CRC Press: Miami, FL.
18. LOOR F, BOESCH D, GAVERIAUX C, JACHEZ B, POURTIER-MANZANEDO A AND EMMER G. (1992). SDZ 280 446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein mediated tumour cell multidrug resistance. Br. J. Cancer, 65, 11 18.
19. MCBURNEY MW AND WHITMORE GF. (1974). Isolation and characterization of folate deficient mutants of Chinese hamster cells. Cell, 2, 173 182.
20. MILLER RL, BUKOWSKI RM, BUDD GT, PURVIS J, WEICK JK, SHEPARD K, MIDHA KK AND GANAPATHI R. (1988). Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: A phase I/II trial. J. Clin. Oncol., 6, 880-888.
21. MIYAMOTO K, INOKO K, WAKUSAWA S, KAJITA S, HASEGAWA T, TAKAGI K AND KOYAMA M. (1993). Inhibition of multidrug resistance by a new staurosporinc derivative, NA-382, in vitro and in vivo. Cancer Res., 53, 1555 1559.
22. MOSMANN T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63.
23. NOOTER K AND HERWEIJER H. (1991). Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer, 63, 663-669.
24. OZOLS RF, CUNNION RE, KLEKER RW, HAMILTON TC, OSTCHEGA Y, PARILLO JE AND YOUNG RC. (1987). Verapamil and doxoruhicin in the treatment of drug-resistant ovarian cancer patients. J. Clin Oncol., 5, 641 647.
25. PATEL NH AND ROTHENBERG ML. (1994). Multidrug resistance in cancer chemotherapy. Invest. New Drug. 12, 1 13.
26. PEARCE HL, SAFA AR, BACH NJ, WINTER MA, CIRTAIN MC AND BECK WT. (1989). Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc. Natl Acad. Sci. USA, 86, 5128-5132.
27. PENNOCK GD, DALTON WS, ROESKE WR, APPLETON CP, MOSLEY K, PLEZIA P, MILLER TP AND SALMON SE. (1991). Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J. Natl Cancer Inst., 83, 105 110.
28. POURTIHR-MANZANHDO A, DIDLER AD, MULLER CD AND LOOR F. (1993). SDZ PSC 833 and SDZ 280 446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells. Anti-Cancer Drugs, 3, 419 421.
29. QUESADA AR, BARBACID MM, MIRA E, ARACIL M AND MARQUEZ G. (1996). Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents. Cancer Lett., 99, 109 114.
30. RADERER M AND SHEITHAUER W. (1993). Clinical trials of agents that reverse multidrug resistance. Cancer, 72, 3553 3563.
31. RAMU A, SPANIER R, RAHAMIMOFF H AND EUKS Z. (1984). Restoration of doxorubicin responsiveness in P388 murine leukaemia cells. Br. J. Cancer, 50, 501-507.
32. THOMSON LA AND BARKER RM. (1973). Isolation of mutants of cultured mammalian cells. Methods Cell Biol., 6, 209-281.
33. TOFFOLI G, SIMONE F, CORONA G, RASCHACK M, CAPPELLETTO B, GIGANTE M AND BOIOCCHI M. (1995). Structure activity relationship of verapamil analogs and reversal of multidrug-resistance. Biochem. Pharmacol., 50, 1245 1255.
34. TSURUO T, IIDA H, TSUKAGOSHI S AND SAKURAI Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41, 1967 1972.
35. TSURUO T, UDA H, NOJIRI M, TSUKAGOSHI S AND SAKURAI Y. (1983). Circumvention of vincristine and doxorubicin resistance in vitro and in vivo by calcium influx blockers. Cancer Res., 43, 2905-2910.
36. TWENTYMAN PR. (1988). Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br. J. Cancer, 57, 254 258.
37. TWENTYMAN PR AND BLEEHEN NM. (1991). Resistance modification by PSC-833 a novel non-immunosuppressive cyclosporin A. Ear. J. Cancer, 27, 1639-1642.
38. TWENTYMAN PR, RHODES T AND RAYNER S. (1994). A comparison of Rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotype. Eur. J. Cancer, 30A, 1360 1369.
39. ZAMORA JM, PEARCE HL AND BECK WT. (1988). Physical chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol., 33, 454 462.